User:XyZAn/sandbox/bi

Timeline

 * 1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on 1 August.
 * 1886: The factory commences production of tartaric acid for use in the food industry (e.g. in baking powder and carbonated beverages).
 * 1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer.
 * 1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale.
 * 1895: Lactic acid is produced on an industrial scale, and is successful commercially.
 * 1917: Professor Heinrich Wieland, chemist, future Nobel Prize winner and cousin of Albert Boehringer, sets up the company’s research department.
 * 1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart.
 * 1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people.
 * 1954: The company hires former Nazi Fritz Fischer after he is released from jail. Fischer was convicted of war crimes and crimes against humanity at the Nuremberg Trials.
 * 1955: The Animal Health division is established as the company acquires Pfizer’s veterinary programme.
 * 1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company’s North American research centre.
 * 1985: The Institute for Molecular Pathology (IMP) is established in Vienna; it opens in 1988.
 * 1986: The biotechnological centre in Biberach begins production of biopharmaceuticals from cell cultures.
 * 1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.
 * 2006: Boehringer sold its natural healthcare company and business Pharmaton SA to IdeaSphere
 * 2008: Boehringer acquired Actimis Pharmaceuticals for $515 million
 * 2010: The company celebrates its 125th anniversary.
 * 2011: Evonik Industries aquires Boehringers Resomer business.
 * 2012: Boehringer acquired the global rights to Funxional Therapeutics’ phase 2 compound FX125L and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases.
 * 2015: In July 2015, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones.  On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer. Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.
 * 2016: In June 2016, the company announced it had struck an asset-swap deal with Sanofi, Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the Merial animal health division (valuing it at €11.4 billion). The deal could mean that Boehringer is now one of the animal healthcare global leaders.

Collaborative research
Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.